An interventional study of Remote monitoring training and Description of the standard care pathway in Epilepsy, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Epilepsy by University Hospital, Toulouse — 5 open to participants now, 6 under way, none of them phase 3. Epilepsy · University Hospital, Toulouse.
Among the 10 studies in Epilepsy by University Hospital, Toulouse, this one is one of 2 that started in 2026, is one of 6 with no phase, and was the 9th registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →5 of the 10 studies in Epilepsy by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
University Hospital, Toulouse · Sites in France
Ages 3–50
University Hospital, Toulouse · Sites in France
Ages 12–65
University Hospital, Toulouse · Sites in France
Ages 18–65
By country, each count listing its studies:
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 60 is above the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 61 across the 6 interventional studies, 113 across the 4 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Toulouse is the lead sponsor of 809 studies on the registry; 211 are open to participants now.
1 of the studies in Epilepsy by University Hospital, Toulouse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03738072University Hospital, ToulouseIntracerebral Electrical Stimulation and the Optimisation of Presurgical Planning in Drug-refractory Partial Epilepsy | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Epilepsy by University Hospital, Toulouse, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Epilepsy is a chronic condition affecting approximately 600,000 people in France. Epilepsy treatment relies on antiepileptic drugs, the effectiveness of which depends on adherence to medication schedule, with missed doses increasing the risk of seizures. As with any chronic illness, epilepsy presents a significant challenge in terms of treatment adherence. Furthermore, despite good medication adherence, 30% of patients remain drug-resistant.
Therefore, the aim is to create a remote monitoring program, supported by a nurse, lasting six months after the introduction of a new antiepileptic drug, to support the patient until their next appointment with a neurologist. This system would optimize and secure the care pathway during treatment changes by improving the detection of side effects and/or a resurgence of seizures requiring medication adjustments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who will benefit from remote monitoring to support them in their changes to antiepileptic treatment
Other: Remote monitoring training · Other: Therapeutic support with a nurse · Diagnostic Test: Questionnaires for the two groups · Other: Satisfaction questionnaire for the group with remote monitoring
Patients who will receive standard care without remote monitoring as part of a change in anti-epileptic treatment
Other: Description of the standard care pathway · Diagnostic Test: Questionnaires for the two groups
Training in the care pathway via remote monitoring software
Description of the standard care pathway with the nurse
Therapeutic support with a nurse who ensures the patient's adherence to remote monitoring at 1 month and 3 months
Quality of life questionnaires at baseline and at 6 months
Satisfaction questionnaire for the group with remote monitoring at 6 months
Describe the evolution of therapeutic adherence
Measurement of the Mascard scale score in 2 groups of patients benefiting or not from the new care and support pathway.
Time frame: 6 months after the inclusion
Evolution of Quality of Life between baseline and 6 months
Evolution of the score on the QOLIE 31 quality of life scale between the beginning and the end of the course between 2 groups
Time frame: 6 months after the inclusion
Description of the care pathway between baseline and 6 months
Description of the number of consultations in both groups between baseline and 6 months
Time frame: 6 months after the inclusion
Description of patient satisfaction with their medical care
Patient satisfaction score on epilepsy care questionnaire
Time frame: 6 months after the inclusion
Evaluation of patient acceptability of remote monitoring
Patient satisfaction questionnaire score regarding the use of the digital tool for the group of patients who received care via remote monitoring
Time frame: 6 months after the inclusion
Evaluation of satisfaction with the use of remote monitoring by the healthcare team
Score on the satisfaction questionnaire regarding the use of remote monitoring by the care team,
Time frame: 6 months after the inclusion
Started Oct 2026 (actual). Primary completion is estimated for Apr 2028, 18 months after the start.
Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 18 months is below that.
Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start May 2026 → Oct 2026, primary completion Nov 2027 → Apr 2028 and completion May 2028 → Oct 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →